It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Sygnature Discovery accelerates inflammation and immunology research by connecting in vitro insights with in vivo outcomes. Our integrated drug discovery services combine biomarker discovery, disease expertise, and advanced pharmacology to deliver robust, decision-ready data. From early screening to translational models, we help you move fast towards clinical success.
Our portfolio spans a wide range of inflammatory and autoimmune conditions, including psoriasis, atopic, dermatitis, inflammatory bowel disease, rheumatoid arthritis, and neuroinflammation.
Every project is tailored to your therapeutic goals, supported by dedicated therapeutic area leads and an expert in vivo pharmacology team. We offer comprehensive in vivo profiling, including physiological measures such as temperature, alongside advanced biomarker analysis using MSD, qPCR and histology to deliver robust, decision-making data.
in vivo Inflammation and Immunology Model Expertise
Our inflammation and immunology portfolio covers systems, tissue-specific and autoimmune conditions. Models can be tailored to your therapeutic modality and endpoints, allowing precise evaluations of efficacy and mechanism of action.
LPS-induced Models
Neuro inflammation, kidney inflammation, and systemic inflammation models provide mechanistic insights and translational data for neurodegenerative and inflammatory disease.
IL-13-Induced Type 2 Inflammation
Systemic IL-13 administration activates the JAK –STAT6 pathway, driving eosinophil recruitment and tissue inflammation. The model provides a relevant platform for evaluating anti-inflammatory therapeutics targeting IL-13 signalling or its downstream pathways.
Carrageenan-Induced Acute Inflammation
Carrageenan-induced paw edema model for screening anti-inflammatory agents, triggered by local release of cytokines and prostaglandins.
Repeated hapten application induces Th2 polarization and dermatitis, mimicking human atopic conditions.
DSS-Induced Colitis
A well-established model of ulcerative colitis, replicating symptoms such as weight loss and diarrhoea for anti-IBD drug evaluation.
Collagen-Induced Arthritis (CIA)
Immunizing with type II collagen induces rheumatoid arthritis-like symptoms for testing anti-arthritic therapies.
Collagen Antibody-Induced Arthritis
Instead of using the antigen, collagen, a cocktail of antibodies against collagen might be used to induce rheumatoid arthritis in rodents with a shorter timeline. This model recapitulates joint and other symptoms similar to the collagen antigen induced CIA model. At Sygnature, we offer the CAIA model in mice which is ideal for rapid screening of novel anti-arthritic agents.
Acute Pharmacodynamic Models
In addition to the various inflammatory and autoimmune disease models, we also can design acute PD models to evaluate inflammation induced by diverse inflammatory agents.
Why Choose Sygnature Discovery for Inflammation and Immunology Support?
Sygnature Discovery offers state-of-the-art models that provide mechanistic insights, measure key biomarkers, and allow rapid evaluation of therapeutic candidates. By combining scientific rigor with a collaborative approach, we deliver reliable, translatable data that accelerates drug discovery and strengthens target validation.
Key Benefits
Sygnature Discovery is a leading partner in advancing inflammation and immunology research offering comprehensive support from early discovery through to clinical development.
Integrated Expertise
Seamless progression from in vitro assays to in vivo models for faster development.
Translational Expertise
Comprehensive model range for evaluating efficacy and mechanism of action.
Ethical Commitment
All studies adhere to the principles of the 3Rs – Replacement, Reduction, and Refinement to uphold the highest standards of scientific integrity and animal welfare.
Acute Kidney Injury (AKI) poses significant clinical challenges due to its rapid onset and high…
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
Yes, ex-vivo analysis such as PK bioanalysis or biomarkers quantification in various tissues can be performed within Sygnature Discovery. We can also assist you in designing the study to accommodate these ex-vivo requirements.
Yes, we can offer histopath support at Sygnature Discovery or via third-party.
With our large amount historical data, our experienced group of statisticians provide necessary power analysis and group size information for each model.
We currently offer inflammatory disease models covering four major sites including skin, joint, gut and lung. In addition, we offer a suite of acute pharmacodynamic, mechanistic inflammation models which are ideal for quick PK-PD assessment. Considering our extensive scientific experience in the I&I area, we can also develop novel models that are not covered within the current scope. Thus, if your assay is not listed, send us a message and we will evaluate the necessary steps to implement your assay of choice.
An error has occurred, please try again later.An error has occurred, please try again later.
You're in the right place!
Peak Proteins has now fully integrated with Sygnature Discovery.
